Where is TL Pharma located?

TL Pharma is headquartered in Italy.

Where does TL Pharma rank among its competitors?

TL Pharma ranks 1050th amongst 1096 active competitors, of which 71 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Caidya, which secured $165M in Jan, 2025.

Who are the top competitors of TL Pharma?

TL Pharma's top competitors include WuXi AppTec, ANI Pharmaceuticals and Ipsen. Among them, Caidya secured the most recent funding round in January, 2025.

TL Pharma - 2026 Company Profile & Competitors

Company Details

Developer of pharmaceutical products including dietary supplements cosmetics and devices. Services include the conception and formulation of health products such as medical devices food for special medical purposes and veterinary items. Support provided includes assistance with product development and manufacturing processes for various therapeutic areas. Technical focus covers fields such as cardiology neurology immunology and metabolic health.

Website: tlpharmaconsulting.it
Email ID: *****@tlpharmaconsulting.it
Phone Number: +39 **********

Key Metrics

Location

Italy

Stage

Unfunded

Ranked

1050^th among 1096 active competitors

Similar Companies

WuXi AppTec & 1140 more

View TL Pharma's full profile

TL Pharma has not raised any funding rounds yet.

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of TL Pharma include WuXi AppTec, ANI Pharmaceuticals and Ipsen. Here is the list of Top 10 competitors of TL Pharma, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	WuXi AppTec 2000, Shanghai (China), Public	Provider of CRO and CDMO services	$40M	Synergis Capital, HongShan & 27 others	75/100
2nd	ANI Pharmaceuticals 1996, Baudette (United States), Public	Manufacturer of pharmaceutical products, including extended-release capsules and immediate-release tablets	-	JPMorgan Chase, Ampersand Capital & 4 others	64/100
3rd	Ipsen 1929, Paris (France), Public	Biopharmaceutical company focused on developing and commercializing innovative treatments in oncology, rare disease, and neuroscience to improve patient health outcomes	-	Digital Pharma Lab, PAI Partners & 2 others	63/100
4th	Zuellig Pharma 1992, Singapore (Singapore), Funding Raised	Provider of clinical research, quality management, logistics, and clinical trial supply services	-	Temasek	61/100
5th	Eurofins Scientific 1987, Luxembourg (Luxembourg), Public	Provider of laboratory testing services and CRO contract research services	-	Europa, CDPQ & 1 others	61/100
6th	Precision Medicine Group 2012, Bethesda (United States), Late Stage	Provider of clinical research, development, and commercialization services for life sciences	$532M	TPG, Oak Investment Partners & 7 others	60/100
7th	EVERSANA 2014, Milwaukee (United States), Funding Raised	Provider of consulting services for drug pricing access, reimbursement, and regulatory support	-	North Sky Capital, Pantheon International ... & 3 others	57/100
8th	China Medical System 1992, Shenzhen (China), Public	Manufacturer of generic formulations	-	CMS Ventures	55/100
9th	Caidya 2003, Morrisville (United States), Series C	CRO focused on clinical development for phases II & III clinical trials and regulatory affair services	$373M	Qiming Venture Partners, Fidelity Investments ... & 22 others	54/100
10th	Tirupati Medicare 1980, Paonta Sahib (India), Series B	Manufacturer of pharmaceutical and nutraceutical products	$51.5M	internationalcylinders.com, TBO & 26 others	54/100
1050th	TL Pharma Italy, Unfunded	Developer of pharmaceutical products including dietary supplements cosmetics and devices	-	-	16/100